In a research report published today, Maxim Group analyst Jason Kolbert maintained a Buy rating on Inovio Pharmaceuticals (NASDAQ:INO) with a $20 price …
In a research report published today, Maxim Group analyst Jason Kolbert maintained a Buy rating on Inovio Pharmaceuticals (NASDAQ:INO) with a price target …
In a research report issued today, Maxim Group analyst Jason Kolbert maintained a Buy rating on Inovio Pharmaceuticals (NASDAQ:INO) with a price target …
In a research report published today, Maxim Group analyst Jason Kolbert reiterated a Buy rating on Inovio Pharmaceuticals (NASDAQ:INO) with a price target …
Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on Inovio Pharmaceuticals (NASDAQ:INO) with a $20, following the company’s second-quarter financial results and update …
In a research report sent to investors today, Maxim Group analyst Jason Kolbert maintained a Buy rating on Inovio Pharmaceuticals (NASDAQ:INO) with a price target …
In a research report issued Wednesday, Maxim Group analyst Jason Kolbert maintained a Buy rating on Inovio Pharmaceuticals (NASDAQ:INO) with a price target …
In a research report released today, Piper Jaffray analyst Charles Duncan reiterated a Overweight rating on Inovio Pharmaceuticals (NASDAQ:INO) with a $29 price target, as the company recently …
In a research report issued today, Maxim Group analyst Jason Kolbert reiterated a Buy rating on Inovio Pharmaceuticals (NYSE:INO) with a $18 price target, as the …
In a research note released August 11, Maxim Group analyst Jason Kolbert reaffirmed a Buy rating on Inovio Pharmaceuticals (INO) with an $18 price target, following the company’s second-quarter results. Inovio …
